Synthesis, characterization and in vitro evaluation of new oxorhenium- and oxotechnetium-CCK4 derivatives as molecular imaging agents for CCK2-receptor targeting

European Journal of Medicinal Chemistry

Volumn 45, Issue 2, 2010, Pages 423-429

  Dorbes, Sandra ^a,b,d   Mestre Voegtlé, Béatrice ^a,b   Coulais, Yvon ^c   Picard, Claude ^a,b   Silvente Poirot, Sandrine ^d   Poirot, Marc ^d   Benoist, Eric ^a,b  

^a CNRS   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c UNIVERSITÉ PAUL SABATIER   (France)

^d INSERM   (France)

Author keywords

CCK4; Receptor targeting peptide; Rhenium; Technetium; Tetradentate chelator

Indexed keywords

AMINOCAPROIC ACID; BETA ALANINE; CHELATING AGENT; CHOLECYSTOKININ B RECEPTOR; CYSTEINE; INOSITOL PHOSPHATE; RHENIUM; TECHNETIUM; TECHNETIUM 99M; TETRAGASTRIN DERIVATIVE;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL STRAIN COS7; CONTROLLED STUDY; DRUG SYNTHESIS; FEASIBILITY STUDY; IN VITRO STUDY; MALE; MOLECULAR IMAGING; NONHUMAN; RAT; SERUM;

ANIMALS; CERCOPITHECUS AETHIOPS; COS CELLS; DRUG STABILITY; HUMANS; MALE; MICE; MOLECULAR IMAGING; ORGANOTECHNETIUM COMPOUNDS; RATS; RECEPTOR, CHOLECYSTOKININ B; RHENIUM; TETRAGASTRIN;

EID: 73949106116     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2009.09.043     Document Type: Article

References (49)

1. Gotthardt M., Boermann O.C., Behr T.M., Behe M.P., and Oyen W.J.G. Curr. Pharm. Des. 10 (2004) 2951-2963
2. Heppeler A., Froidevaux S., Eberle A.N., and Maecke H.R. Curr. Med. Chem. 7 (2000) 971-994
3. Okarvi S. J. Pept. Res. 63 (2004) 460-468
4. Okarvi S. Nucl. Med. Commun. 20 (1999) 1093-1112
5. Blok D., Feitsma R.I.J., Vermeij P., and Pauwels E.K.J. Eur. J. Nucl. Med. 26 (1999) 1511-1519
6. Reubi J.C., and Maecke H.R. J. Nucl. Med. 49 (2008) 1735-1738
7. Okarvi S. Cancer Treat. Rev. 34 (2008) 13-26
8. Weiner R.E., and Thakur M.L. Biodrugs 19 (2005) 145-163
9. Wank S.A. Am. J. Physiol. 274 (1998) G607-G613
10. Reubi J.C., Schaer J.C., and Waser B. Cancer Res. 57 (1997) 1377-1386
11. Gotthardt M., Behe M.P., Beuter D., Battmann A., Bauhofer A., Schurrat T., Schipper M., Pollum H., Oyen W.J.G., and Behr T.M. Eur. J. Nucl. Med. Mol. Imaging 33 (2006) 1273-1279
12. Nock B.A., Maina T., Behe M., Nikolopoulou A., Gotthardt M., Schmitt J.S., Behr T.M., and Maecke H.R. J. Nucl. Med. 46 (2005) 1727-1736
13. Laverman P., Behe M., Oyen W.J.G., Willems P.H., Corstens F.H., Behr T.M., and Boerman O.C. Bioconjugate Chem. 15 (2004) 561-568
14. Behe M., and Behr T.M. Biopolymers (peptide science) 66 (2002) 399-418
15. Kwekkeboom D.J., Bakker W.H., Kooij P.P., Erion J., Srinivasan A., de Jong M., Reubi J.C., and Krenning E.P. Eur. J. Nucl. Med. 27 (2000) 1312-1317
16. For MG analogs see
17. Good S., Walter M.A., Waser B., Wang X., Muller-Brand J., Behe M.P., Reubi J.C., and Maecke H.R. Eur. J. Nucl. Med. Mol. Imaging 35 (2008) 1868-1877
18. Trejtnar F., Laznicek M., Laznickova A., Kopecky M., Petrik M., Behe M., Schmidt J., Maecke H.R., Maina T., and Nock B. Anticancer Res. 27 (2007) 907-912
19. Mather S.J., McKenzie A.J., Sosabowski J.K., Morris T.M., Ellison D., and Watson S.A. J. Nucl. Med. 48 (2007) 615-622
20. von Guttenberg E., Dietrich H., Skvortsova I., Gabriel M., Virgolini I.J., and Decristoforo C. Eur. J. Nucl. Med. Mol. Imaging 34 (2007) 1209-1218
21. Sosabowski J.K., Lee M., Dekker B.A., Simmons B.P., Singh S., Beresford H., Hagan S.A., McKenzie A.J., Mather S.J., and Watson S.A. Eur. J. Pharm. Sci. 31 (2007) 102-111
22. For CCK8 analogs see
23. d'Andrea L.D., Testa I., Panico M.R., Di Stasi R., Caraco C., Tarallo L., Arra C., Barbieri A., Romanelli A., and Aloj L. Biopolymers (peptide science) 90 (2008) 707-712
24. Aloj L., Caraco C., Panico M., Zannetti A., Del Vecchio S., Tesauro D., De Luca S., Arra C., Pedone C., Morelli G., and Salvatore M. J. Nucl. Med. 45 (2004) 485-494
25. Aloj L., Panico M., Caraco C., Del Vecchio S., Arra C., Affuso A., Accardo A., Mansi R., Tesauro D., De Luca S., Pedone C., Visentin R., Mazzi U., Morelli G., and Salvatore M. Cancer Biother. Radiopharm. 19 (2004) 93-98
26. Reubi J.C., Waser B., Schaer J.C., Laederach U., Erion J., Srinivasan A., Schmidt M.A., and Bugaj J.E. Eur. J. Nucl. Med. 25 (1998) 481-490
27. Behr T.M., and Behe M. Semin. Nucl. Med. 32 (2002) 97-102
28. Behr T.M., Behe M., Angerstein C., Gratz S., Mach R., Hagemann L., Jenner N., Stiehler M., Franck-Raue K., Raue F., and W. Clin. Cancer Res. 5 (1999) 3124s-3138s
29. Okarvi S. Med. Res. Rev. 24 (2004) 357-397
30. Garcia-Garayoa E., Schweinsberg C., Maes V., Brans L., Blauenstein P., Tourwe D.A., Schibli R., and Schubiger P.A. Bioconjugate Chem. 19 (2008) 2409-2416
31. Visentin R., Rossin R., Giron M.C., Dolmella A., Bandoli G., and Mazzi U. Inorg. Chem. 42 (2003) 950-959
32. Deutsch E., Libson K., Vander Heyden J.L., Ketring A.R., and Maxon H.R. Nucl. Med. Biol. 13 (1986) 465-477
33. J. Chatt, G.A. Rowe, J. Chem. Soc. (1962) 4019-4033.
34. Le Gal J., and Benoist E. Eur. J. Org. Chem. (2006) 1483-1488
35. Silvente-Poirot S., and Wank S.A. J. Biol. Chem. 271 (1996) 14698-14706
36. Silvente-Poirot S., Escrieut C., Gales C., Fehrentz J.A., Escherich A., Wank S.A., Martinez J., Moroder L., Maigret B., Buisson M., Vaysse N., and Fourmy D. J. Biol. Chem. 274 (1999) 23191-23197
37. Le Gal J., Latapie L., Gressier M., Coulais Y., Dartiguenave M., and Benoist E. Org. Biomol. Chem. 2 (2004) 876-883
38. Unpublished work.
39. Visentin R., Giron M.C., Bello M., and Mazzi U. Nucl. Med. Biol. 31 (2004) 655-662
40. Wentworth P. Trends Biotechnol. 17 (1999) 448-452
41. Le Gal J., Tisato F., Bandoli G., Gressier M., Jaud J., Michaud S., Dartiguenave M., and Benoist E. Dalton Trans. (2005) 3800-3807
42. Liu S. Chem. Soc. Rev. 33 (2004) 445-461
43. Koenig J.A., and Edwardson J.M. Trends Pharmacol. Sci. (TiPS) 18 (1997) 276-287
44. Langer M., and Beck-Sickinger A.G. Curr. Med. Chem. 1 (2001) 71-93
45. Rosenkilde M.M., and Schwartz T.W. Mol. Pharmacol. 57 (1999) 602-609
46. Garcia-Garayoa E., Ruegg D., Blauenstein P., Zwimpfer M., Ullah Khan I., Maes V., Blanc A., Beck-Sickinger A.G., Tourwe D.A., and Schubiger P.A. Nucl. Med. Biol. 34 (2007) 17-28 and references therein
47. Antunes P., Ginj M., Walter M.A., Chen J., Reubi J.C., and Maecke H.R. Bioconjugate Chem. 18 (2007) 84-92
48. Smith C.J., Gali H., Sieckman G.L., Higginbotham C., Volkert W.A., and Hoffman T.J. Bioconjugate Chem. 14 (2003) 93-102
49. The CCK4 moiety being crucial for receptor binding, it seems difficult to modify this sequence by introduction of D-aminoacid to enhance the short biological half-life. Methylation of the nitrogen of the Trp-Nle peptide bond should be a solution to prevent proteolysis.